

**Type of article:** Research article

**Title:** EXPANDING THE VECTOR CONTROL TOOLBOX FOR MALARIA ELIMINATION: A SYSTEMATIC REVIEW OF THE EVIDENCE

**Authors:** Yasmin A Williams<sup>1\*†</sup>, Lucy S Tusting<sup>2†</sup>, Sophia Hocini, Patricia M Graves<sup>3</sup>, Gerry F Killeen<sup>4, 5</sup>, Immo Kleinschmidt<sup>6, 7, 8</sup>, Fredros O Okumu<sup>4</sup>, Richard GA Feachem<sup>1</sup>, Allison Tatarsky<sup>1</sup>, Roly D Gosling<sup>1</sup>

†Contributed equally

**Number of tables:** 3

**Number of figures:** 2

**Author affiliations:** **1** Malaria Elimination Initiative, Global Health Group, University of California, San Francisco, USA, **2** Big Data Institute, Nuffield Department of Medicine, University of Oxford, UK, **3** College of Public Health, Medical and Veterinary Sciences and Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia, **4** Environmental Health and Ecological Sciences Department, Ifakara Health Institute, Tanzania, **5** Vector Biology Department, Liverpool School of Tropical Medicine, UK, **6** MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, UK (I Kleinschmidt, PhD), **7** School of Pathology, Faculty of Health Sciences, University of Witwatersrand, South Africa, **8** Elimination 8, Windhoek, Namibia

**Corresponding author:**

Yasmin A Williams

Email: [Yasmin.Williams@ucsf.edu](mailto:Yasmin.Williams@ucsf.edu)

Telephone: +1 415 502 5495

**Keywords:** malaria, malaria elimination, vector control, vector control tools, vector-borne diseases

1 **Abstract**

2 **Background**

3 Additional vector control tools (VCTs) are needed to supplement insecticide-treated nets (ITNs) and  
4 indoor residual spraying (IRS) to achieve malaria elimination in many settings. To identify options for  
5 expanding the malaria vector control toolbox, we conducted a systematic review of the availability and  
6 quality of the evidence for 21 malaria VCTs, excluding ITNs and IRS.

7 **Methods**

8 Six electronic databases and grey literature sources were searched from January 1, 1980 to September 28,  
9 2015 to identify systematic reviews, Phase I-IV studies, and observational studies that measured the effect  
10 of malaria VCTs on epidemiological or entomological outcomes across any age groups in all malaria-  
11 endemic settings. Eligible studies were summarized qualitatively, with quality and risk of bias  
12 assessments undertaken where possible. Of 17,912 studies screened, 155 were eligible for inclusion and  
13 were included in a qualitative synthesis.

14 **Results**

15 Across the 21 VCTs, we found considerable heterogeneity in the volume and quality of evidence, with  
16 seven VCTs currently supported by at least one Phase III community-level evaluation measuring  
17 parasitologically-confirmed malaria incidence or infection prevalence (insecticide-treated clothing and  
18 blankets, insecticide-treated hammocks, insecticide-treated livestock, larval source management (LSM),  
19 mosquito-proofed housing, spatial repellents, and topical repellents). The remaining VCTs were  
20 supported by one or more Phase II (n=13) or Phase I evaluation (n=1). Overall the quality of the evidence  
21 base remains greatest for LSM and topical repellents, relative to the other VCTs evaluated, although  
22 existing evidence indicates that topical repellents are unlikely to provide effective population-level  
23 protection against malaria.

24 **Conclusions**

25 Despite substantial gaps in the supporting evidence, several VCTs may be promising supplements to ITNs  
26 and IRS in appropriate settings. Strengthening operational capacity and research to implement  
27 underutilized VCTs, such as LSM and mosquito-proofed housing, while expanding the evidence base for  
28 promising supplementary VCTs that are locally tailored, should be considered central to global malaria  
29 elimination efforts.

## 30 **Introduction**

31 Great advances have been made in malaria control and elimination, with a 37% global decline in malaria  
32 incidence during 2000-2015.<sup>1,2</sup> New targets include the elimination of malaria from at least 35 countries  
33 between 2015 and 2030,<sup>1</sup> with renewed calls for eradication within a generation.<sup>3</sup> In sub-Saharan Africa  
34 (SSA), vector control with insecticide-treated nets (ITNs) and indoor residual spraying (IRS) has averted  
35 an estimated 524 million malaria cases since 2000.<sup>2</sup> However, there remain important obstacles to  
36 achieving and sustaining elimination, including operational inefficiencies that lead to low effective  
37 coverage,<sup>4</sup> insecticide resistance,<sup>5</sup> and residual transmission mediated by mosquito behaviours such as  
38 outdoor biting and resting, feeding upon animals, and early exit from houses immediately after entering,  
39 which are not effectively targeted by ITNs and IRS.<sup>6,7</sup>

40

41 To achieve malaria elimination goals in the face of such challenges, what evidence-based vector control  
42 tools (VCTs) can national malaria control and elimination programs access today or within the next  
43 decade, to supplement ITNs and IRS? To date, ITNs and IRS are the only VCTs to have been  
44 recommended for wide-scale implementation by the World Health Organization (WHO), while larval  
45 source management (LSM) and personal protection measures against mosquitoes are recommended in  
46 some settings.<sup>1</sup> Recognising the need for additional VCTs, WHO recently established mechanisms for  
47 expedited vector control recommendations, including new technical expert panels,<sup>8</sup> and the recently-  
48 formed Innovation to Impact (I2I) initiative also aims to support VCT development and  
49 implementation.<sup>9,10</sup> Here, to guide the identification of promising VCTs to expand the vector control  
50 toolbox for malaria elimination, we conducted a systematic review to collate published and unpublished  
51 evidence on the effect of selected VCTs on confirmed clinical malaria and malaria infection in people of  
52 any ages and on *Anopheles*-specific entomological outcomes in malaria-endemic regions. This is the first  
53 study to collate systematically the evidence across the spectrum of malaria vector control, excluding ITNs  
54 and IRS.

55

56 **Methods**

57 We conducted a systematic review of the literature to summarize the availability and quality of the  
58 evidence for 21 malaria VCTs, excluding ITNs and IRS (Table 1). We followed guidelines of the  
59 Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) (Additional File 1).<sup>11</sup>  
60 The candidate VCTs for evaluation were selected through consultation with experts (including a meeting  
61 held on June 1-3, 2015 in San Francisco, US) and the review of policy documents.<sup>9,12</sup>

62

63 [Insert Table 1 here]

64

65 ***Eligibility criteria***

66 Studies were included that evaluated any VCT targeting *Anopheles* mosquitoes in Table 1 and that met  
67 the eligibility criteria described in Table 2. Eligible study designs were categorized as observational,  
68 Phase I, Phase II, or Phase III studies. Observational studies included those with case-control, cohort or  
69 cross-sectional designs. Phase I studies were defined as laboratory assays to determine the mode of  
70 action. Phase II were defined as semi-field, experimental hut, and small-scale field studies, generally with  
71 entomological outcomes. Finally, Phase III studies were defined as trials measuring the efficacy of the  
72 VCT against epidemiological outcomes under optimal conditions.<sup>13</sup>

73

74 [Insert Table 2 here]

75

76 ***Search strategy and selection criteria***

77 PubMed; EMBASE; LILACS; the Cochrane Infectious Diseases Group Specialized Register; Cochrane  
78 Central Register of Controlled Trials (CENTRAL), published in The Cochrane Library; and the Meta-  
79 Register of Controlled Trials (mRCT) were searched for studies published in English from January 1,  
80 1980 to September 28, 2015 with the search terms described in Additional File 2. Search dates were  
81 restricted because systematic reviews included in this review captured the historical evidence on older

82 VCTs, including LSM. Additionally, we searched reference lists of identified studies and contacted  
83 authors and field experts for unpublished data. To identify studies in progress, we searched the  
84 ClinicalTrials.gov registry. YAW and SH independently screened titles and abstracts, followed by full-  
85 text screening of relevant studies for eligibility using a standard form in Qualtrics (Qualtrics, Provo, UT).  
86 Disagreements were resolved by LST.

87

### 88 ***Data abstraction***

89 Study characteristics (including participants, intervention, control group, outcomes, and sample size, as  
90 applicable) and findings were double-entered into a standard form in Microsoft Excel by YAW and  
91 verified by LST. Since we aimed to assess evidence availability, not VCT efficacy, we did not combine  
92 studies in a meta-analysis. Instead, for each VCT we summarized the current evidence by the number and  
93 type of completed studies and, where possible, stratified this information by outcome. We presented in  
94 tables all eligible studies for every VCT, except for VCTs with a recent ( $\leq 5$  years old) high-quality  
95 systematic review (Measurement Tool to Assess Systematic Reviews (AMSTAR)<sup>14</sup> score  $\geq 50\%$ ; see  
96 below), for which we presented only the systematic review.<sup>13</sup>

97

### 98 ***Quality of systematic reviews and risk of bias in Phase III studies***

99 The quality of systematic reviews was assessed using the AMSTAR tool.<sup>14</sup> Risk of bias for randomized  
100 controlled trials (RCTs), controlled before-and-after studies (CBA), cross-over studies, and interrupted  
101 time-series studies was assessed using the Effective Practice and Organization of Care (EPOC) tool.<sup>15</sup>  
102 Risk of bias was not assessed for Phase I, Phase II, or observational studies due to wide heterogeneity in  
103 study designs. We did not perform a statistical test for publication bias because we did not conduct any  
104 meta-analyses.

105

### 106 **Results**

107 The search results yielded 17,912 unique studies after removing duplicates (Figure 1). A total of 155  
108 studies met the eligibility criteria and were included in the qualitative synthesis; these were of the  
109 following designs: systematic reviews (n=7); Phase III (n=7), Phase II (n=76), and Phase I (n=54)  
110 experimental studies; and cross-sectional (n=7), case-control (n=3), and cohort (n=1) observational  
111 studies (Figure 2, Additional File 3). Methodological quality was variable across the seven eligible  
112 systematic reviews, with AMSTAR scores ranging from 18% to 100% (Additional File 4A). The  
113 systematic reviews of LSM (n=2), mosquito-proofed housing (n=1), and topical repellents (n=1) were  
114 determined to be of the highest quality (AMSTAR scores  $\geq 50\%$ ), while those of spatial repellents (n=2)  
115 and zooprophylaxis (n=1) were judged to be of lower quality. Of the 21 VCTs evaluated, we identified  
116 seven with one or more completed Phase III study, including some that were included in systematic  
117 reviews: LSM, insecticide-treated clothing and blankets, insecticide-treated hammocks, insecticide-  
118 treated livestock, mosquito-proofed housing, spatial repellents, and topical repellents; with recent, high-  
119 quality systematic reviews available for LSM, mosquito-proofed housing, and topical repellents (Table 3).

120

121 [Insert Figure 1 here]

122

123 [Insert Figure 2 here]

124

125 [Insert Table 3 here]

126

### 127 ***VCTs with a recent systematic review***

128 *Larval source management (LSM)*: A 2013 Cochrane review compared biological control with  
129 larvivorous fish to biological control without larvivorous fish.<sup>16</sup> No eligible studies included in this  
130 review measured malaria incidence, entomological inoculation rate (EIR), or adult vector density (Table  
131 3). Nine quasi-experimental studies measured larval mosquito density, with variable effects. A second  
132 2013 Cochrane review compared LSM (excluding biological control with larvivorous fish) with no

133 LSM.<sup>17</sup> Compared to the control, LSM reduced malaria incidence by 74% in two cluster RCTs, but there  
134 was no consistent effect on malaria incidence in three CBA studies. GRADE quality of evidence ranged  
135 from very low to moderate. Parasite prevalence was reduced by 89% in another cluster-RCT and by an  
136 average of 68% in five CBA studies. GRADE quality of evidence was assessed to be moderate for both  
137 subgroups.

138  
139 *Mosquito-proofed housing:* A 2015 systematic review included one Phase III RCT and four observational  
140 studies in a meta-analysis comparing screened with unscreened housing, in which findings on the effect  
141 on clinical malaria, malaria infection, and anaemia in children were inconsistent (Table 3).<sup>18</sup> A further 15  
142 observational studies were included in a meta-analysis comparing ‘modern’ housing (e.g. brick or cement  
143 walls and metal roofs) with ‘traditional’ housing (e.g. mud walls, thatched roofs, open eaves, and no  
144 screening).<sup>18</sup> Modern housing was associated with a 45-65% lower odds of clinical malaria and 47%  
145 lower odds of malaria infection, compared to traditional housing, although the GRADE quality of  
146 evidence was assessed to be very low.

147  
148 *Topical repellents:* In a systematic review of experimental studies comparing topical repellents with no  
149 repellent or placebo repellents,<sup>19</sup> the risk of *P. falciparum* malaria or infection was reduced by 18% in six  
150 RCTs and one CBA. *P. vivax* malaria or infection was reduced by 20% in five RCTs and one CBA,  
151 compared to the control, but neither reduction was statistically significant. EPOC risk of bias in the  
152 included studies ranged from low to unclear (Table 3).

153  
154 ***Other VCTs with a Phase III evaluation***

155 *Insecticide-treated clothing and blankets:* Malaria incidence was measured in two RCTs with low to  
156 moderate risk of bias, where the effect of insecticide-treated clothing and blankets ranged from an 81%  
157 decrease to no effect, compared to the control (Table 3).<sup>20,21</sup> Outcomes assessed by the four Phase II  
158 studies included parasite prevalence (n=2) and adult mosquito mortality (n=2) (Additional File 3B).



159

160 *Insecticide-treated hammocks:* Malaria incidence and parasite prevalence were measured in two Phase III  
161 RCTs, with EPOC risk of bias for both studies assessed to be low (Table 3). In Venezuela, insecticide-  
162 treated hammocks reduced malaria incidence by 56% and parasite prevalence by 83%, compared to the  
163 control,<sup>22</sup> and in Vietnam a greater reduction in malaria incidence and parasite prevalence was observed  
164 in the intervention arm than in the control (footnote to Table 3).<sup>23</sup> One Phase II study measured adult *An.*  
165 *gambiae* mortality, hut entry, and blood feeding inhibition (Additional File 3C).

166

167 *Insecticide-treated livestock:* Malaria incidence and parasite prevalence were measured in one Phase III  
168 cross-over study, with EPOC risk of bias assessed to be moderate, in which insecticide-treated livestock  
169 reduced malaria incidence by 31-56% and parasite prevalence by 40-54% compared to the control, though  
170 the effect was not consistently significant (Table 3).<sup>24</sup> Entomological outcomes measured in five Phase II  
171 studies included adult mosquito mortality and blood feeding preference (Additional File 3C).

172

173 *Spatial repellents:* Two systematic reviews included laboratory and Phase II field studies only, with no  
174 meta-analyses (Table 3).<sup>25,26</sup> No eligible studies measured the effect of spatial repellents on malaria  
175 incidence. Parasite prevalence was measured in two RCTs, with the EPOC risk of bias assessed to be low  
176 for both studies, and in one cross-sectional study. In the RCTs, transfluthrin coils reduced parasite  
177 prevalence by 77% compared to long-lasting insecticide-treated nets (LLINs) alone and by 94% when  
178 combined with LLINs, compared to no intervention in China;<sup>27</sup> metofluthrin mosquito coils reduced  
179 parasite prevalence by 52% compared to a placebo in Indonesia.<sup>28</sup> Entomological outcomes measured in  
180 23 Phase II studies and one Phase I study included human biting rate (HBR), adult mosquito mortality,  
181 and repellency (Additional File 3C).

182

183 ***VCTs with no Phase III evaluation***

184 Fourteen VCTs had Phase I, II, and/or observational evidence only: adult sterilization by contamination,  
185 attractive toxic sugar baits (ASTB), other attract-and-kill mechanisms, biological control of adult vectors,  
186 eave tubes and eave baffles, endectocide administration in humans, endectocide administration in  
187 livestock, genetic modification, insecticide-treated durable wall linings, insecticide-treated fencing,  
188 larvicide application by autodissemination, push-pull systems, space spraying (ground application), and  
189 zooprophyllaxis (Figure 2, Additional File 3C, Additional File 3D). For these VCTs we included a total of  
190 103 studies, comprising 42 Phase II, 51 Phase I, and 10 observational studies. All VCTs had at least one  
191 eligible Phase II study, except endectocide administration in humans. Three VCTs had at least one  
192 eligible observational study: endectocide administration in humans, spatial repellents, and  
193 zooprophyllaxis. For zooprophyllaxis, we also identified one systematic review (AMSTAR score 18%),  
194 which reported no meta-analysis.<sup>29</sup> Entomological outcomes were measured for all VCTs, while  
195 epidemiological outcomes were measured for two VCTs only (space spraying and zooprophyllaxis).

196

## 197 **Discussion**

198 To strengthen malaria vector control and maintain progress towards elimination, additional malaria vector  
199 control tools are needed to supplement ITNs and IRS. In this systematic review assessing the availability  
200 and quality of evidence for 21 supplementary VCTs, we included 155 studies dating from January 1, 1980  
201 to September 28, 2015. This is the first study to collate evidence systematically across the malaria vector  
202 control toolbox beyond ITNs and IRS. Our study highlights the expanding pipeline of research into  
203 supplementary VCTs, while identifying substantial heterogeneity in the availability and quality of the  
204 evidence required by WHO to provide normative guidance on implementation (i.e. standardized  
205 epidemiological data from Phase III trials in multiple settings).<sup>9,30</sup>

206

207 For each VCT, we summarized the current evidence by the number and quality of studies and stratified  
208 this information by outcome where possible. Within this framework, the evidence base was the most  
209 extensive for LSM and topical repellents, which both have multiple published Phase III evaluations and

210 recent systematic reviews assessed to be of high methodological quality. While the evidence for LSM was  
211 assessed to be of very low to moderate quality,<sup>17</sup> combinations of larviciding and environmental  
212 management have been effective in reducing malaria transmission in certain eco-epidemiological settings  
213 in Africa and Asia and larviciding has been recommended by WHO as a supplementary intervention in  
214 SSA since 2013.<sup>2</sup> This recommendation is limited to discrete settings where habitats are relatively ‘few,  
215 fixed, and findable’; far narrower than settings in high-income countries where larviciding is used  
216 routinely and successfully for mosquito and disease control.<sup>2</sup> In contrast, the evidence for topical  
217 repellents is of relatively high quality<sup>19</sup> but indicates that they are unsuitable as a large-scale public health  
218 intervention, although they can provide individual protection against mosquitoes.<sup>19</sup> We identified five  
219 further VCTs with at least one Phase III evaluation with epidemiological outcomes: insecticide-treated  
220 clothing and blankets, insecticide-treated hammocks, insecticide-treated livestock, mosquito-proofed  
221 housing, and spatial repellents. These VCTs offer additional options for supplementing ITNs and IRS,  
222 often with complementary modes of action. Further Phase III community level trials will help to clarify  
223 their roles in malaria vector control in different epidemiological settings.<sup>6,31,32</sup>

224  
225 Our assessment of evidence was based on study design and outcomes, but in the future it may be  
226 necessary to consider evidence complementary to standard epidemiological assessments.<sup>33</sup> First, making  
227 recommendations across diverse transmission settings and local vector ecologies is difficult. Although  
228 Cochrane reviews remain the gold standard in evidence-based policy, it is often inappropriate to combine  
229 findings from studies across different eco-epidemiological settings when VCT efficacy is tied to local  
230 transmission ecology.<sup>16,17</sup> Second, some emerging VCTs remain years away from accumulating a full  
231 dossier of epidemiological evidence, and although further Phase III studies are planned,<sup>34</sup> nearing  
232 completion,<sup>35</sup> or recently concluded,<sup>36</sup> we identified fourteen VCTs for which no Phase III  
233 epidemiological data were available within the search dates. Demonstrating protection against disease  
234 and/or infection is critical before any VCTs can be recommended for large-scale deployment.<sup>13</sup> However,  
235 in some circumstances evidence of effect might be built by adopting underutilized VCTs as

236 supplementary interventions within a ‘learning-by-doing’ framework. This iterative approach involves the  
237 incorporation of rigorous monitoring and evaluation of epidemiological and entomological outcomes in  
238 control and intervention areas, to support the gradual scale-up of additional VCTs within existing  
239 programme infrastructure, such as through adaptable Phase IV effectiveness studies.<sup>6,13,37</sup> For example,  
240 while only one RCT of house screening for malaria control has been completed,<sup>38</sup> a large body of  
241 observational evidence suggests that screened housing is associated with reduced malaria risk and  
242 national malaria control programs are encouraged to explore opportunities to build ‘healthier’ housing.<sup>39</sup>  
243  
244 Direct transition to Phase IV ‘learning-by-doing’ approaches are controversial and inappropriate for new  
245 VCTs or VCTs with a poor evidence base.<sup>13</sup> The history of ITNs and IRS demonstrates varying routes to  
246 establishing effectiveness against malaria disease or infection; ITNs underwent rigorous evaluation  
247 through Phase III RCTs,<sup>40</sup> while IRS effectiveness was established decades before evaluation in RCTs.<sup>41</sup>  
248 Given adequate funding, promising new VCTs should reach approval far faster than ITNs, but depending  
249 on the entomological mode of action, efficacy of a VCT in one ecological setting is not always guaranteed  
250 elsewhere. Recent examples illustrate the importance of demonstrating efficacy against epidemiological  
251 as well entomological outcomes. Topical repellents reduce vector biting, but it took a cluster RCT with  
252 epidemiological outcomes to show their unsuitability as a generalizable public health intervention due to  
253 the high user compliance required.<sup>42</sup> Conversely, odour baited traps have recently been shown to reduce  
254 malaria infection prevalence in a rigorous RCT, but entomological data from that study suggest caution  
255 before deploying this VCT at scale in different settings since the traps were largely effective against *An.*  
256 *funestus* only.<sup>36</sup> Such information may be obtainable through ‘learning-by-doing’ evaluations, as long as  
257 evaluations of outcomes are of high quality. Research institutions will need to support control programs  
258 in design, technical capacity, and analysis to ensure meaningful findings are obtained from Phase IV  
259 effectiveness evaluations.  
260  
261 Despite limited evidence on their efficacy against malaria, the fourteen VCTs with no complete Phase III

262 evaluation offer diverse modes of action to complement those of ITNs and IRS within a comprehensive  
263 intervention package. Some may only be suitable for niche application, for example, insecticide-treated  
264 clothing may be effective for individuals working outdoors at night, but not as a general public health  
265 intervention. Others such as insecticide-treated durable wall linings (which are impregnable with  
266 alternative insecticides to those used for IRS) might reduce reliance on the main classes of insecticides  
267 currently available for ITNs and IRS; a multi-country Phase III evaluation is currently underway.<sup>43</sup>  
268 Similarly, administration of endectocides such as ivermectin to people or livestock could circumvent  
269 insecticide resistance and target zoophagic behaviours in vectors, although epidemiological effect remains  
270 to be demonstrated.<sup>44,45</sup> Some emerging VCTs might reduce transmission by vectors biting outdoors,  
271 including larvicide application by autodissemination using pyriproxyfen, which targets immature  
272 mosquitoes regardless of adult biting and resting behaviour.<sup>46</sup> Some emerging VCTs exploit vulnerability  
273 in alternative vector life stages to those targeted by ITNs and IRS. ATSBs, which target sugar feeding,  
274 consistently reduced adult mosquito density and HBR in Phase II studies in Israel, Mali, and the USA.  
275 However, Phase III trials of ATSBs with epidemiological outcomes are certainly needed. Genetic  
276 modification of mosquitoes aims to suppress populations thereby reducing vectorial competence,<sup>47</sup> but our  
277 review highlights how such approaches have yet to progress fully beyond laboratory evaluations.  
278  
279 Overall the expansion of research on supplementary VCTs is encouraging, but arguably the first step to  
280 strengthening vector control for malaria elimination is to improve operational capacity to deliver and  
281 sustain existing interventions effectively.<sup>48</sup> For example, major inefficiencies persist within LLIN delivery  
282 systems across SSA, limiting population access.<sup>49</sup> There are also opportunities to explore new or  
283 improved delivery mechanisms for existing supplementary interventions, such as larviciding.<sup>50</sup> Some  
284 VCTs may not be highly effective individually, but could potentially be highly effective when used in  
285 combinations. Use of mathematical models could help to address such questions, where no  
286 epidemiological evidence is available. Critical to improving vector control is the development of strong  
287 local entomological capacity,<sup>51</sup> together with better integration of control across vector-borne diseases and

288 government sectors.<sup>48,52</sup>

289

290 Our study has several limitations. First, our VCTs of interest were selected *a priori* through expert  
291 consultation and are not an exhaustive list. Second, our search was restricted to English language papers  
292 only, potentially excluding experiences from some regions. Third, we did not combine data across studies  
293 in a meta-analysis, precluding evaluation of effect on entomological and epidemiological outcomes and  
294 statistical tests for publication bias. Fourth, for studies with entomological outcomes there was no  
295 mechanism to standardize outcomes and assess how heterogeneity in the choice of control affected study  
296 findings. Fifth, this review focused on individual interventions, and did not consider the potential benefits  
297 of combining two or more of the new VCTs in communities already using ITNs and IRS. Finally, we did  
298 not assess methodological quality and risk of bias in Phase I and II studies due to heterogeneity in study  
299 design.

300

301 In conclusion, our review highlights the expanding pipeline of research into new and underutilized  
302 approaches to malaria vector control and the critical need to fund robust evaluation of supplementary  
303 VCTs. Despite substantial gaps in the supporting evidence, several VCTs are promising supplements to  
304 ITNs and IRS. Strengthening operational capacity to implement and evaluate underutilized VCTs, such as  
305 LSM and mosquito-proofed housing, while expanding the evidence base for newer VCTs through  
306 strategic assessment of existing evidence and rigorous epidemiological evaluation, should be central to  
307 global malaria elimination efforts.

308 **Additional files**

309 **Additional file 1:** PRISMA statement

310 **Additional file 2:** Search strategy

311 **Additional file 3:** Characteristics and summary of findings of systematic reviews, Phase I-III, and  
312 observational studies

313 **Additional file 4:** Quality assessment of systematic reviews and risk of bias in Phase III studies

314

315 **Contributors**

316 RDG, AT, and GFK conceived of the study. YAW, LST, RDG, GFK, and AT developed the study  
317 design. YAW, LST, and SH searched the literature. YAW and LST extracted the data and prepared the  
318 manuscript. PMG advised on the systematic review. All authors had access to study data and reviewed the  
319 final manuscript. All authors read and approved the final manuscript.

320

321 **Author's information**

322 Yasmin A Williams and Lucy S Tusting are joint first authors.

323

324 **Acknowledgements**

325 This work was supported by the University of California, Group Health Group Malaria Elimination  
326 Initiative through funding from The Parker Foundation ([www.parker.org](http://www.parker.org)). LST is a Skills Development  
327 Fellow (#N011570) jointly funded by the UK Medical Research Council (MRC) and the UK Department  
328 for International Development (DFID) under the MRC/DFID Concordat agreement  
329 (<http://www.mrc.ac.uk/>). FOO is also supported by a Wellcome Trust Intermediate Research Fellowship  
330 (#WT102350/Z/13/Z). We thank Dr William Hawley for his review of the manuscript, Dr Jimee Hwang  
331 for input on the study protocol, and Nicolas Simon for his help with study screening.

332

333 **Conflict of interests**

334 The authors declare that they have no conflict of interests. The study sponsors had no role in study design,  
335 in the collection, analysis and interpretation of data, in writing the report, and in the decision to submit for  
336 publication.

## References

- 337 1. World Health Organization (2015). “Global Technical Strategy for Malaria 2016–2030”. Geneva:  
338 World Health Organization. <http://www.who.int/malaria/publications/atoz/9789241564991/en/>  
339 (accessed May 27, 2016).
- 340 2. Global Malaria Programme (2015). World Malaria Report 2015. Geneva: World Health Organization.
- 341 3. Gates, B., & Chambers, R. (2015). “From aspiration to action: what will it take to end malaria?”.  
342 <http://endmalaria2040.org/> (accessed Feb 18, 2016).
- 343 4. Bhatt, S., Weiss, D. J., Mappin, B., Dalrymple, U., Cameron, E., Bisanzio, D., Smith, D. L., Moyes,  
344 C. L., Tatem, A. J., Lynch, M., Fergus, C. A., Yukich, J., Bennett, A., Eisele, T. P., Kolaczinski, J.,  
345 Cibulskis, R. E., Hay, S. I. & Gething, P. W. (2015). “Coverage and system efficiencies of  
346 insecticide-treated nets in Africa from 2000 to 2017”. *eLife*, **4**.
- 347 5. Ranson, H. & Lissenden, N. (2016). “Insecticide resistance in African Anopheles mosquitoes: a  
348 worsening situation that needs urgent action to maintain malaria control”. *Trends Parasitol*, **32**, 187-  
349 196.
- 350 6. Killeen, G. F. (2014). “Characterizing, controlling and eliminating residual malaria transmission”.  
351 *Malar J*, **13**, 330.
- 352 7. Govella, N. J. & Ferguson, H. (2012). “Why use of interventions targeting outdoor biting mosquitoes  
353 will be necessary to achieve malaria elimination”. *Frontiers in Physiology*, **3**, 199.
- 354 8. World Health Organization Malaria Policy Advisory Committee (2015). “Innovation to Impact –  
355 WHO change plan for strengthening innovation, quality and use of vector control tools”. Geneva:  
356 World Health Organization.
- 357 9. World Health Organization Vector Control Advisory Group (2013). “Report on the first meeting of the  
358 WHO Vector Control Advisory Group”. Geneva: World Health Organization Vector Control  
359 Advisory Group.
- 360 10. Innovation to Impact (I2I) (2016). <http://innovationtoimpact.org/>. (accessed Aug 20, 2016).
- 361 11. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, T. P. (2009). “Preferred Reporting Items  
362 for Systematic Reviews and Meta-Analyses: The PRISMA Statement”. *PLoS Med*, **6**, e1000097.
- 363 12. World Health Organization Vector Control Advisory Group (2014). “Report on the second meeting of  
364 the WHO Vector Control Advisory Group”. Geneva: World Health Organization Vector Control  
365 Advisory Group.
- 366 13. Wilson, A. L., Boelaert, M., Kleinschmidt, I., Pinder, M., Scott, T. W., Tusting, L. S. & Lindsay, S.  
367 W. (2015). “Evidence-based vector control? Improving the quality of vector control trials”. *Trends*  
368 *Parasitol*, **8**, 380–90.
- 369 14. Shea, B. J., Grimshaw, J. M., Wells, G. A., Boers, M., Andersson, N., Hamel, C., Porter, A. C.,  
370 Tugwell, P., Moher, D. & Bouter, L. M. (2007). “Development of AMSTAR: a measurement tool to  
371 assess the methodological quality of systematic reviews”. *BMC Med Res Methodol*, **7**, 10.



- 372 15. Effective Practice and Organisation of Care (EPOC) (2015). “Suggested risk of bias criteria for EPOC  
373 reviews”. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health  
374 Services.
- 375 16. Walshe, D. P., Garner, P., Abdel-Hameed Adeel, A. A., Pyke, G. H. & Burkot, T. (2013).  
376 “Larvivorous fish for preventing malaria transmission”. *Cochrane Database Syst Rev*, **12**, Cd008090.
- 377 17. Tusting, L. S., Thwing, J., Sinclair, D., Fillinger, U., Gimnig, J., Bonner, K. E., Bottomley, C. &  
378 Lindsay, S. W. (2013). “Mosquito larval source management for controlling malaria”. *Cochrane*  
379 *Database Syst Rev*, **8**, Cd008923.
- 380 18. Tusting, L. S., Ippolito, M. M., Willey, B. A., Kleinschmidt, I., Dorsey, G., Gosling, R. D. &  
381 Lindsay, S. W. (2015). “The evidence for improving housing to reduce malaria: a systematic review  
382 and meta-analysis”. *Malar J*, **14**, 209.
- 383 19. Wilson, A. L., Chen-Hussey, V., Logan, J. G. & Lindsay, S. W. (2014). “Are topical insect repellents  
384 effective against malaria in endemic populations? A systematic review and meta-analysis”. *Malar J*,  
385 **13**, 446.
- 386 20. Macintyre, K., Sosler, S., Letipila, F., Lochigan, M., Hassig, S., Omar, S. A. & Githure, J. (2003). “A  
387 new tool for malaria prevention?: Results of a trial of permethrin-impregnated bedsheets (shukas) in  
388 an area of unstable transmission”. *Int J Epidemiol*, **32**, 157-160.
- 389 21. Rowland, M., Durrani, N., Hewitt, S., Mohammed, N., Bourna, M. & Carneiro, I. (1999).  
390 “Permethrin-treated protection against chaddars and top-sheets: appropriate technology for malaria in  
391 Afghanistan and other complex emergencies”. *Trans R Soc Trop Med Hyg*, **93**, 465–72.
- 392 22. Magris, M., Rubio-Palis, Y., Alexander, N., Ruiz, B., Galván, N., Frias, D., Blanco, M. & Lines, J.  
393 (2007). “Community-randomized trial of lambda-cyhalothrin-treated hammock nets for malaria  
394 control in Yanomami communities in the Amazon region of Venezuela”. *Trop Med Int Health*, **12**,  
395 392–403.
- 396 23. Thang, N. D., Erhart, A., Speybroeck, N., Xia, N. X., Thanh, N. N., Van Ky, P., Hung, L. X., Thuan,  
397 L. K., Coosemans, M. & D'alessandro, U. (2009). “Long-lasting insecticidal hammocks for  
398 controlling forest malaria: A community-based trial in a rural area of Central Vietnam”. *PLoS ONE*,  
399 **4**.
- 400 24. Rowland, M., Durrani, N., Kenward, M., Mohammed, N., Urahman, H. & Hewitt, S. (2001). “Control  
401 of malaria in Pakistan by applying deltamethrin insecticide to cattle: A community-randomised trial”.  
402 *Lancet*, **357**, 1837–41.
- 403 25. Lawrence, C. E. & Croft, A. M. (2004). “Do mosquito coils prevent malaria? A systematic review of  
404 trials”. *J Travel Med*, **11**, 92–6.
- 405 26. Ogoma, S. B., Moore, S. J. & Maia, M. F. (2012). “A systematic review of mosquito coils and  
406 passive emanators: defining recommendations for spatial repellency testing methodologies”. *Parasit*  
407 *Vectors*, **5**, 287.
- 408 27. Hill, N., Zhou, H. N., Wang, P., Guo, X., Carneiro, I. & Moore, S. J. (2014). “A household  
409 randomized, controlled trial of the efficacy of 0.03% transfluthrin coils alone and in combination with

- 410 long-lasting insecticidal nets on the incidence of *Plasmodium falciparum* and *Plasmodium vivax*  
411 malaria in Western Yunnan Province, China”. *Malar J*, **13**, 208.
- 412 28. Syafruddin, D., Bangs, M. J., Sidik, D., Elyazar, I., Asih, P. B., Chan, K., Nurleila, S., Nixon, C.,  
413 Hendarto, J., Wahid, I., Ishak, H., Bogh, C., Grieco, J. P., Achee, N. L. & Baird, J. K. (2014). “Impact  
414 of a spatial repellent on malaria incidence in two villages in Sumba, Indonesia”. *Am J Trop Med Hyg*,  
415 **91**, 1079–87.
- 416 29. Donnelly, B., Berrang-Ford, L., Ross, N. A. & Michel, P. (2015). “A systematic, realist review of  
417 zooprophylaxis for malaria control”. *Malar J*, **14**, 313.
- 418 30. WHO Malaria Policy Advisory Committee (2012). “Technical Expert Group (TEG) on malaria vector  
419 control: Terms of Reference”. Geneva: World Health Organization.
- 420 31. Lobo N.F., Achee N.L., & Syafruddin D. (2014). “Spatial repellent products for control of vector-  
421 borne diseases - malaria - Indonesia (SR-M-IDR)”. University of Notre Dame.  
422 <https://clinicaltrials.gov/show/NCT02294188> (accessed Jun 10, 2016).
- 423 32. Pinder, M., Conteh, L., Jeffries, D., Jones, C., Knudsen, J., Kandeh, B., Jawara, M., Sicuri, E.,  
424 D'Alessandro, U., Lindsay, S.W. (2016). “The RooPfs study to assess whether improved housing  
425 provides additional protection against clinical malaria over current best practice in The Gambia: study  
426 protocol for a randomized controlled study and ancillary studies”. *Trials*, **17**(1), 275.
- 427 33. Vontas, J., Moore, S., Kleinschmidt, I., Ranson, H., Lindsay, S., Lengeler, C., Hamon, N., Mclean, T.  
428 & Hemingway, J. (2014). “Framework for rapid assessment and adoption of new vector control  
429 tools”. *Trends Parasitol*, **30**, 191–204.
- 430 34. Thomas, M., Knols, B., & N'guessan, R. (2015). “Transition of eave tubes from concept to  
431 implementation”. Pennsylvania State University, 2015.
- 432 35. Mtove, G., Mugasa, J.P., Messenger, L.A., Malima, R.C., Mangesho, P., Magogo, F., Plucinski, M.,  
433 Hashimu, R., Matowo, J., Shepard, D., Batengana, B., Cook, J., Emidi, B., Halasa, Y., Kaaya, R.,  
434 Kihombo, A., Lindblade, K.A., Makenga, G., Mpangala, R., Mwambuli, A., Mzava, R., Mziray, A.,  
435 Olang, G., Oxborough, R.M., Seif, M., Sambu, E., Samuels, A., Sudi, W., Thomas, J., Weston, S.,  
436 Alilio, M., Binkin, N., Gimnig, J., Kleinschmidt, I., McElroy, P., Moulton, L.H., Norris, L., Ruebush,  
437 T., Venkatesan, M., Rowland, M., Mosha, F.W., Kisinza, W.N. (2016). “The effectiveness of non-  
438 pyrethroid insecticide-treated durable wall lining to control malaria in rural Tanzania: study protocol  
439 for a two-armed cluster randomized trial”. *BMC Public Health*, **16**(1), 633.
- 440 36. Homan, T., Hiscox, A., Mweresa, C. K., Masiga, D., Mukabana, W. R., Oria, P., Maire, N., Pasquale,  
441 A. D., Silkey, M., Alaii, J., Bousema, T., Leeuwis, C., Smith, T. A. & Takken, W. (2016). “The effect  
442 of mass mosquito trapping on malaria transmission and disease burden (SolarMal): a stepped-wedge  
443 cluster-randomised trial”. *The Lancet*, **388**(10050), 1193–201.
- 444 37. Global Malaria Programme (2014). “Control of residual malaria parasite transmission, Guidance note  
445 – September”. Geneva: World Health Organization.
- 446 38. Kirby, M.J., Ameh, D., Bottomley, C., Green, C., Jawara, M., Milligan, P.J., Snell, P.C., Conway,  
447 D.J., & Lindsay, S.W. (2009). “Effect of two different house screening interventions on exposure to  
448 malaria vectors and on anaemia in children in The Gambia: a randomised controlled trial”. *The*  
449 *Lancet*, **374**(9694), 998–1009.

- 450 39. Roll Back Malaria (2015). “Draft consensus statement on housing and malaria”. Geneva: World  
451 Health Organization.
- 452 40. Darriet, F. D. R., Robert, V., Vien, N. T., & Carnevale, P. (1984). “Evaluation of the efficacy of  
453 permethrin-impregnated intact and perforated mosquito nets against vectors of malaria”. Geneva:  
454 World Health Organization.
- 455 41. Sadasivaia, S., Tozan, Y. & Breman, J. (2007). “Dichlorodiphenyltrichloroethane (DDT) for indoor  
456 residual spraying in Africa: how can it be used for malaria control?” *Am J Trop Med Hyg*, **77**, 249–  
457 63.
- 458 42. Chen-Hussey, V., Carneiro, I., Keomanila, H., Gray, R., Bannavong, S., Phanalasy, S. & Lindsay,  
459 S.W. (2013). “Can topical insect repellents reduce malaria? A cluster-randomised controlled trial of  
460 the insect repellent *N,N-diethyl-m-toluamide* (DEET) in Lao PDR”. *PLoS ONE*, **8**(8), e70664.
- 461 43. Messenger, L. A., Matias, A., Manana, A. N., Stiles-Ocran, J. B., Knowles, S., Boakye, D. A.,  
462 Coulibaly, M. B., Larsen, M.-L., Traoré, A. S., Diallo, B., Konaté, M., Guindo, A., Traoré, S. F.,  
463 Mulder, C. E., Le, H., Kleinschmidt, I., & Rowland, M. (2012). “Multicentre studies of insecticide-  
464 treated durable wall lining in Africa and South-East Asia: entomological efficacy and household  
465 acceptability during one year of field use”. *Malar J*, **11**(1), 1–13.
- 466 44. Chaccour, C.J., Rabinovich, N.R., Slater, H., Canavati, S. E., Bousema, T., Lacerda, M., Ter Kuile,  
467 F., Drakeley, C., Bassat, Q., Foy, B. D. & Kobylinski, K. (2015). “Establishment of the ivermectin  
468 research for malaria elimination network: updating the research agenda”. *Malar J*, **14**, 243.
- 469 45. Foy, B.D., Kobylinski, K.C., Da Silva, I.M., Rasgon, J.L. & Sylla, M. (2011). “Endectocides for  
470 malaria control”. *Trends Parasitol*, **27**, 423–8.
- 471 46. Mbare, O., Lindsay, S. & Fillinger, U. (2014). “Pyriproxyfen for mosquito control: female  
472 sterilization or horizontal transfer to oviposition substrates by *Anopheles gambiae sensu stricto* and  
473 *Culex quinquefasciatus*”. *Parasit Vectors*, **7**(1), 280.
- 474 47. Alphey, L., & Alphey, N. (2014). “Five things to know about genetically modified (GM) insects for  
475 vector control”. *PLoS Pathog*, **10**(3), e1003909.
- 476 48. Brady, O.J., Godfray, H.C.J., Tatem, A.J., Gething, P.W., Cohen, J.M., Mckenzie, F.E., Perkins, T.A.,  
477 Reiner, R.C., Tusting, L.S., Sinka, M.E., Moyes, C.L., Eckhoff, P.A., Scott, T.W., Lindsay, S.W.,  
478 Hay, S.I. & Smith, D.L. (2016). “Vectorial capacity and vector control: reconsidering sensitivity to  
479 parameters for malaria elimination”. *Trans R Soc Trop Med Hyg*, **110**(2), 107–17.
- 480 49. Bhatt, S. & Gething, P.W. (2014). “Insecticide-treated nets (ITNs) in Africa 2000-2016: coverage,  
481 system efficiency and future needs for achieving international targets”. *Malar J*, **13**, O29.
- 482 50. Knapp, J., Macdonald, M., Malone, D., Hamon, N. & Richardson, J. (2015). “Disruptive technology  
483 for vector control: the Innovative Vector Control Consortium and the US Military join forces to  
484 explore transformative insecticide application technology for mosquito control programmes”. *Malar*  
485 *J*, **14**, 371.
- 486 51. Mnzava, A.P., Macdonald, M.B., Knox, T.B., Temu, E.A. & Shiff, C.J. (2014). “Malaria vector  
487 control at a crossroads: public health entomology and the drive to elimination”. *Trans R Soc Trop*  
488 *Med Hyg*, **108**(9), 550–4.

- 489 52. World Health Organization (2009). "Development of a global action plan for integrated vector  
490 management (IVM)". Geneva: World Health Organization.
- 491 53. Atkins, D., Best, D., Briss, P.A., Eccles, M., Falck-Ytter, Y., Flottorp, S., Guyatt, G.H., Harbour,  
492 R.T., Haugh, M.C., Henry, D., Hill, S., Jaeschke, R., Leng, G., Liberati, A., Magrini, N., Mason, J.,  
493 Middleton, P., Mrukowicz, J., O'Connell, D., Oxman, A.D., Phillips, B., Schünemann, H.J., Edejer,  
494 T., Varonen, H., Vist, G.E., Williams, J.W. Jr., & Zaza, S.; GRADE Working Group. (2004).  
495 "Grading quality of evidence and strength of recommendations". *BMJ*, **328**(7454), 1490.

